Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

European Journal of Clinical Pharmacology

Volumn 68, Issue 11, 2012, Pages 1509-1516

  Kosoglou, Teddy ^a   Zhu, Yali ^a   Xuan, Fengjuan ^a   Black, Laura ^a   Johnson Levonas, Amy O ^a   Martinho, Monika ^a   Statkevich, Paul ^a   Cutler, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

PAR 1; Pharmacodynamics; Pharmacokinetics; Vorapaxar; Warfarin

Indexed keywords

VORAPAXAR; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; LETHARGY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; DRUG MONITORING; HALF-LIFE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LACTONES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROTHROMBIN TIME; PYRIDINES; RECEPTOR, PAR-1; STATISTICS AS TOPIC; STEREOISOMERISM; WARFARIN; YOUNG ADULT;

EID: 84867572073     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1271-0     Document Type: Article

References (20)

1. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J et al (2008) Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51:3061-3064 (Pubitemid 351821864)
2. Chintala M, Vemulapalli S, Kurowski S, Sabin C, Reynolds D, Prevete K, Friedrichs G (2008) SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Atheroscler Thromb Vasc Biol e-136
3. Kosoglou T, Reyderman L, Tiessen RG, van Vliet A, Fales RR, Keller R, Yang B, Cutler DL (2012) Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol 68:249-258
4. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P (2010) Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 17:156-164
5. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20-33
6. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E (2009) Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 158:335-341
7. Coumadin Tablets/Coumadin for Injection [prescribing information] (2010) Bristol-Myers Squibb, Princeton, NJ
8. Hirsh J (1991) Oral anticoagulant drugs. N Engl J Med 324:1865-1875
9. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119:8S-21S (Pubitemid 32154192)
10. Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41:1633-1652 (Pubitemid 36543387)
11. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan V (2005) Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 5:193-202 (Pubitemid 40852221)
12. Ghosal A, Lu X, Penner N, Gao L, Ramanathan R, Chowdhury SK, Kishnani NS, Alton KB (2011) Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos 39:30-38
13. Shanmugam S, Lee ES, Jeong TC, Yong CS, Choi HG, Woo JS, Yoo BK (2007) The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of warfarin. Arch Pharm Res 30:898-904
14. Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Schiller J, Meehan AG et al (2012) No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol 68:291-300
15. Lai AA, Levy RH, Cutler RE (1978) Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 24:316-323 (Pubitemid 9025587)
16. Leucuta SE, Vlase L (2006) Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 1:5-20
17. Jacobs T, De Ridder F, Rusch S, Van Peer A, Molenberghs G, Bijnens L (2008) Including information on the therapeutic window in bioequivalence acceptance. Pharm Res 25:2628-2638
18. Johnston M, Harrison L, Moffat K, Willan A, Hirsh J (1996) Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. J Lab Clin Med 128:214-217 (Pubitemid 27506451)
19. Kirkwood TB (1983) Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 49:238-244 (Pubitemid 13060101)
20. Reyderman L, Kosoglou T, Tseng J, Xuan F, Schiller J, Cutler DL, Kim K (2011) The effect of food and antacid on pharmacokinetics (PK) of SCH 530348 in healthy subjects. Clin Pharmacol Ther 85 [Suppl 1]:S21